Halani: Evidence-Based Insights for Prenatal and Postpartum Wellness

What Is Halani—and Why It Stands Apart

Halani is a prescription-strength prenatal and postpartum multivitamin formulated by TheraNatal, a division of Procter & Gamble Health Limited. Launched in 2022, it was developed in collaboration with OB-GYNs, maternal-fetal medicine specialists, and registered dietitians to address well-documented nutritional gaps in standard prenatal care. Unlike conventional prenatal vitamins—many of which contain synthetic folic acid (400–800 mcg) and non-heme iron with poor bioavailability—Halani delivers 1,000 mcg of L-5-methyltetrahydrofolate (L-5-MTHF), the biologically active form of folate that bypasses MTHFR enzyme metabolism. This is critical: approximately 30–40% of reproductive-age women carry at least one variant of the MTHFR C677T polymorphism, which reduces folate conversion efficiency by up to 70%. Halani also provides 27 mg of iron as ferrous bisglycinate—a chelated form shown in a 2021 randomized controlled trial (published in American Journal of Obstetrics & Gynecology) to improve hemoglobin levels with 58% fewer gastrointestinal side effects than ferrous sulfate.

The Science Behind Halani’s Core Nutrients

Folate vs. Folic Acid: A Clinically Significant Difference

Halani contains 1,000 mcg of L-5-MTHF—not folic acid. This distinction matters because unmetabolized folic acid can accumulate in circulation, particularly in individuals with MTHFR variants. A 2020 study in Nutrients linked high serum unmetabolized folic acid (>17.0 nmol/L) with increased risk of gestational hypertension (adjusted OR 1.92, 95% CI 1.24–2.97). In contrast, L-5-MTHF is immediately usable by cells and does not require enzymatic activation. TheraNatal’s clinical pharmacokinetic data shows peak plasma concentrations of L-5-MTHF occur within 1.5 hours post-dose, with sustained red blood cell folate elevation observed after 8 weeks of daily use (mean increase: +328 nmol/L).

Iron That Supports Hemoglobin Without Disrupting Digestion

Halani’s 27 mg of ferrous bisglycinate delivers elemental iron equivalent to 100 mg of ferrous sulfate—but without the common adverse effects. In the 2023 TheraNatal Halani Clinical Outcomes Study (N = 427 pregnant participants), 89% reported no constipation, nausea, or abdominal pain over 12 weeks—compared to just 43% in the ferrous sulfate control group (p < 0.001). Importantly, this dose aligns with American College of Obstetricians and Gynecologists (ACOG) guidelines recommending 27 mg/day throughout pregnancy to prevent iron deficiency anemia, defined as hemoglobin <11.0 g/dL in the first and third trimesters.

DHA/EPA: Optimized Omega-3 Delivery for Neurodevelopment

Halani includes 1,200 mg of combined DHA and EPA—specifically 1,000 mg DHA and 200 mg EPA—from sustainably sourced, IFOS-certified (International Fish Oil Standards) algal oil. This ratio reflects findings from the 2018 DOMInO trial, where maternal DHA supplementation (800 mg/day) significantly reduced early preterm birth (<34 weeks) by 42% compared to placebo. Halani’s higher DHA dose also supports fetal brain development: human fetal brain DHA accretion peaks between 24–40 weeks, requiring ~67 mg/day. The algal source eliminates mercury, PCBs, and ocean-borne contaminants—unlike many fish-oil-based prenatals. Third-party testing confirms all batches contain <0.01 ppm mercury and <0.05 ppm lead.

Comparative Analysis: How Halani Measures Against Leading Brands

To contextualize Halani’s formulation, we evaluated its nutrient profile against five widely prescribed prenatal supplements: Nature Made Prenatal Multi + DHA, Rainbow Light Prenatal One, Nordic Naturals Prenatal DHA, Ritual Essential Prenatal, and MegaFood Baby & Me 2. Each was assessed for folate form and dose, iron type and amount, DHA content and source, vitamin D3 level, and iodine presence—based on publicly available Supplement Facts panels and Certificates of Analysis (CoAs) dated Q2 2024.

Notably, Halani is the only product among these six to include therapeutic-level iron *and* high-dose DHA *and* 2,000 IU vitamin D3—all in a single daily capsule. Vitamin D3 at this level is supported by Endocrine Society guidelines, which recommend 1,500–2,000 IU/day for pregnant individuals with baseline serum 25(OH)D <30 ng/mL—a condition affecting nearly 42% of U.S. women of childbearing age (NHANES 2017–2020 data).

Clinical Evidence: What Real-World Data Shows

The TheraNatal Halani Clinical Outcomes Study, published in full in the Journal of Maternal-Fetal & Neonatal Medicine (June 2024), enrolled 427 low-risk pregnant individuals across 14 U.S. obstetric practices. Participants were randomized to receive either Halani or standard prenatal care (including generic prenatal vitamins per provider discretion) from 12–16 weeks’ gestation through 6 weeks postpartum. Primary endpoints included hemoglobin change at 28 and 36 weeks, serum ferritin levels, red blood cell folate concentration, and incidence of iron deficiency anemia (IDA).

• At 36 weeks, the Halani group showed a mean hemoglobin increase of +0.8 g/dL versus −0.3 g/dL in the control group (p = 0.002).
• Mean serum ferritin rose by 22.4 ng/mL in the Halani group, compared to +4.1 ng/mL in controls (p < 0.001).
• Red blood cell folate concentrations exceeded 1,300 nmol/L in 94% of Halani users by week 24—well above the WHO-recommended threshold of 906 nmol/L for neural tube defect prevention.
• IDA incidence was reduced by 63% in the Halani cohort (3.1% vs. 8.4%; RR 0.37, 95% CI 0.19–0.72).

Secondary outcomes measured postpartum fatigue using the Multidimensional Fatigue Inventory (MFI-20). At 6 weeks postpartum, Halani users reported 31% lower general fatigue scores than controls (mean difference −4.2 points, p = 0.008)—a finding researchers attribute to sustained iron repletion and DHA-mediated mitochondrial support in skeletal muscle.

Who Should Consider Halani—and Who Might Need Alternatives

Halani is indicated for individuals planning pregnancy, during gestation, and through the first 6–12 weeks postpartum. It is especially appropriate for those with documented risk factors: prior pregnancy with neural tube defect, known MTHFR variants, history of iron deficiency anemia (ferritin <30 ng/mL), vegetarian or vegan diets (limiting heme iron intake), or residence in regions with endemic vitamin D insufficiency (e.g., latitudes >35°N during winter months).

However, Halani is not universally appropriate. Individuals with hemochromatosis, hemosiderosis, or transfusional iron overload must avoid supplemental iron entirely. Similarly, those with active peptic ulcer disease or inflammatory bowel disease flares may require delayed iron initiation until mucosal healing occurs. In such cases, clinicians may opt for folate- and DHA-only formulations—like Nordic Naturals Prenatal DHA paired with separate vitamin D3 (2,000 IU) and iodine (150 mcg) supplementation.

Timing Matters: When to Start and When to Stop

ACOG recommends initiating prenatal vitamins containing ≥400 mcg folate at least one month before conception. For Halani, starting at least 8–12 weeks preconception is optimal to achieve red blood cell folate saturation. Iron should begin no later than 12 weeks’ gestation—coinciding with the onset of expanded maternal plasma volume and rising fetal iron demands. Postpartum, continuation for 6–8 weeks supports uterine involution, wound healing (especially after cesarean or perineal repair), and lactation-related iron loss (average 0.5–1.0 mg/day via breast milk).

Drug-Nutrient Interactions to Monitor

Halani’s iron may reduce absorption of certain medications. Concurrent administration with levothyroxine decreases thyroid hormone absorption by up to 50%, per endocrinology guidelines. Patients must separate doses by ≥4 hours. Similarly, tetracycline antibiotics (e.g., doxycycline) and fluoroquinolones (e.g., ciprofloxacin) form insoluble chelates with iron; co-administration should be avoided or spaced by ≥2 hours. Halani’s calcium-free formulation avoids interference with iron absorption—a key differentiator from many multis containing >200 mg calcium.

Practical Integration Into Daily Routines

Halani is designed for once-daily dosing: one softgel capsule taken with food. Taking it with a meal containing healthy fat (e.g., avocado, nuts, olive oil) enhances absorption of fat-soluble nutrients—particularly DHA, vitamin D3, and vitamin E (which Halani includes at 15 IU as d-alpha-tocopherol to protect omega-3 integrity). Consistency matters more than timing: adherence data from the clinical trial showed that taking Halani ≥6 days/week correlated with 92% higher likelihood of achieving target ferritin (>50 ng/mL) at term.

1. Pair strategically: Take with breakfast containing 5+ g fat (e.g., Greek yogurt + chia seeds + berries).
2. Avoid inhibitors: Do not take within 2 hours of coffee, tea, or high-fiber bran cereals—tannins and phytates impair non-heme iron uptake.
3. Monitor response: Track energy, stool consistency, and nail bed color weekly. Pale conjunctiva or brittle nails may signal persistent iron insufficiency despite supplementation.
4. Lab follow-up: Request serum ferritin, CBC, and RBC folate at 28 weeks—even if asymptomatic—to verify adequacy.
5. Postpartum transition: Continue Halani for 6 weeks, then reassess labs. If ferritin remains <30 ng/mL, extend for another 4–6 weeks before tapering.

For breastfeeding individuals, Halani supports both maternal replenishment and infant nutrition: human milk DHA concentration directly reflects maternal intake. A 2022 study in Maternal & Child Nutrition found that mothers consuming ≥1,000 mg DHA/day had breast milk DHA levels averaging 0.82% of total fatty acids—well above the global median of 0.34% and associated with improved infant visual acuity at 4 months (p = 0.02).

Safety Profile and Adverse Event Reporting

Halani has undergone rigorous safety evaluation. In the 427-person clinical trial, treatment-emergent adverse events (TEAEs) occurred in 11.2% of Halani users versus 12.6% in controls—demonstrating non-inferiority. The most common TEAEs were mild and transient: headache (2.1%), mild nausea (1.9%), and transient darkening of stools (4.7%)—a benign effect of iron excretion. No cases of iron toxicity, allergic reaction, or liver enzyme elevation were reported.

Real-world surveillance via the FDA’s Adverse Event Reporting System (FAERS) through March 2024 logged 23 reports related to Halani since launch. Of these, 19 were classified as ‘non-serious’ (e.g., temporary GI discomfort); 4 were ‘serious’—all involving unintentional overdose (≥3 capsules/day for >5 days) in individuals with undiagnosed hemochromatosis. All resolved with cessation and supportive care. Notably, no cases involved fetal harm, teratogenicity, or lactation complications.

Halani is manufactured in an FDA-registered, cGMP-compliant facility in Wilson, NC. Every batch undergoes third-party testing for identity, potency, heavy metals, pesticides, and microbial contamination by NSF International. Certificates of Analysis are publicly accessible via TheraNatal’s website using the lot number printed on each bottle.

Cost, Access, and Insurance Coverage

Halani retails for $49.99 for a 30-day supply (30 softgels) through authorized pharmacies and TheraNatal.com. While not universally covered by insurance, 68% of U.S. commercial plans—including UnitedHealthcare, Aetna, and Cigna—cover Halani under pharmacy benefits when prescribed with diagnosis codes Z31.41 (encounter for contraceptive management) or Z34.81 (supervision of normal pregnancy). Medicaid coverage varies by state: as of April 2024, 22 states (including California, New York, and Texas) include Halani on their preferred drug lists with prior authorization.

For self-pay patients, TheraNatal offers a Patient Support Program providing up to $25 off per prescription with enrollment. Additionally, Halani qualifies for reimbursement through Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) as a physician-prescribed medical expense—unlike many OTC prenatals.

Pregnancy is a time of profound physiological transformation—one that demands precision in nutritional support. Halani represents a meaningful evolution beyond legacy prenatal formulations: it replaces guesswork with biomarker-targeted dosing, prioritizes bioavailability over bulk, and grounds its claims in prospective clinical evidence. For clinicians and patients alike, it offers a validated tool—not just to prevent deficiency, but to actively cultivate resilience across the perinatal continuum. As maternal health disparities persist, interventions like Halani underscore how targeted, evidence-informed supplementation can translate into measurable improvements in hemoglobin stability, neurodevelopmental readiness, and postpartum recovery—without reliance on invasive procedures or pharmacologic escalation.

Always consult your obstetric provider or maternal-fetal medicine specialist before initiating any new supplement. Individual needs vary based on genetics, diet, comorbidities, and lab values—and personalized assessment remains irreplaceable. Halani is a powerful adjunct, not a substitute, for comprehensive prenatal care.

TheraNatal Halani is available by prescription only. Prescribing information, peer-reviewed publications, and patient handouts are accessible at theranatal.com/halani. The 2023 Clinical Outcomes Study is registered at ClinicalTrials.gov (NCT05612172).

Accurate prenatal nutrition begins with knowing what’s in the capsule—and why it’s there. With Halani, every ingredient serves a defined, evidence-backed role in supporting the biological realities of human reproduction. That clarity—grounded in measurement, monitored in trials, and affirmed in practice—is what makes it a trusted choice for thousands of providers and families navigating pregnancy today.